Roberts S. Negrin

Roberts S. Negrin's AcademicInfluence.com Rankings

Roberts S. Negrin

Philosophy

#6158

World Rank

#9148

Historical Rank

Logic

#3345

World Rank

#4490

Historical Rank

philosophy Degrees

Roberts S. Negrin

Biology

#8333

World Rank

#11395

Historical Rank

Immunology

#472

World Rank

#489

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Roberts S. Negrin's Degrees

Doctorate Medicine Stanford University
PhD Immunology Stanford University

Why Is Roberts S. Negrin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roberts S. Negrin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation (2003) (1236)
Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. (1999) (951)
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. (2001) (947)
Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity (1991) (569)
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. (2006) (488)
A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. (1994) (457)
Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. (2005) (441)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey (2015) (423)
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. (2008) (387)
Thomas' hematopoietic cell transplantation (2003) (379)
Visualizing the kinetics of tumor-cell clearance in living animals. (1999) (374)
Use of reporter genes for optical measurements of neoplastic disease in vivo. (2000) (373)
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. (2004) (365)
In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. (2005) (365)
Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. (2005) (359)
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. (1996) (355)
Shifting foci of hematopoiesis during reconstitution from single stem cells (2003) (352)
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. (1999) (344)
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. (2003) (336)
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. (1993) (330)
Protective conditioning for acute graft-versus-host disease. (2005) (323)
High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. (1997) (320)
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. (2010) (296)
Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model (1997) (296)
Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. (1993) (285)
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. (2014) (276)
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. (1993) (271)
Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. (2003) (268)
Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy (2006) (263)
Noninvasive assessment of tumor cell proliferation in animal models. (1999) (253)
Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation (2009) (251)
Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells (2009) (236)
Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. (2001) (234)
Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. (1990) (231)
In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. (2007) (225)
Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. (1989) (222)
Advancing animal models of neoplasia through in vivo bioluminescence imaging. (2002) (216)
Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. (1995) (215)
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. (2005) (215)
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. (1996) (207)
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. (2004) (203)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (187)
Thalidomide as salvage therapy for chronic graft-versus-host disease. (1995) (180)
Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. (2011) (179)
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease (2006) (175)
The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. (2008) (174)
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. (2008) (169)
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. (2000) (167)
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. (2009) (162)
Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. (1993) (158)
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. (2001) (156)
Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. (2011) (148)
Bioluminescence imaging of lymphocyte trafficking in vivo. (2001) (145)
Transplanted Terminally Differentiated Induced Pluripotent Stem Cells Are Accepted By Immune Mechanisms Similar To Self-Tolerance (2014) (142)
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. (2012) (138)
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial (2021) (135)
A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. (1998) (132)
Activated T cells and cytokine-induced CD3+CD56+ killer cells (1997) (132)
Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. (2011) (130)
Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. (1998) (129)
Propagation of large numbers of T cells with natural killer cell markers (1994) (128)
Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. (1995) (128)
Silencing Human NKG2D, DAP10, and DAP12 Reduces Cytotoxicity of Activated CD8+ T Cells and NK Cells1 (2005) (128)
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. (2007) (126)
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. (2005) (123)
Dynamic assessment of quality of life after autologous bone marrow transplantation. (1992) (122)
Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. (2008) (120)
Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation (2017) (113)
Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study (2006) (113)
Mouse models of bone marrow transplantation. (2008) (108)
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. (2012) (107)
Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. (2011) (106)
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. (2008) (103)
Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. (2005) (100)
Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. (2008) (98)
Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. (2001) (97)
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. (1996) (95)
Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. (1995) (95)
Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. (2001) (93)
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. (2007) (91)
High-Dose N-Acetylcysteine in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease (2005) (91)
Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. (1994) (90)
Evaluation of effector cell fate and function by in vivo bioluminescence imaging. (2003) (88)
Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. (2006) (87)
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. (1996) (87)
Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. (2010) (84)
CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. (2014) (83)
Impact of Mammalian Target of Rapamycin Inhibition on Lymphoid Homing and Tolerogenic Function of Nanoparticle-Labeled Dendritic Cells following Allogeneic Hematopoietic Cell Transplantation1 (2008) (83)
Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T‐regulatory cells (2009) (82)
Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. (2013) (82)
Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. (1997) (81)
A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. (2017) (80)
Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. (2009) (79)
Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. (1993) (77)
Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. (1991) (76)
Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. (1993) (75)
Graft-versus-host disease versus graft-versus-leukemia. (2015) (75)
TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. (2016) (75)
Understanding immune cell trafficking patterns via in vivo bioluminescence imaging (2002) (74)
A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. (2000) (73)
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. (2011) (73)
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. (2001) (72)
Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis (2000) (71)
Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation (2014) (70)
Studies of ex Vivo Activated and Expanded CD8+ NK-T Cells in Humans and Mice (2002) (69)
Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. (1994) (68)
Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy (2008) (68)
Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. (2004) (67)
Energy-transducing H+-ATPase of Escherichia coli. Reconstitution of proton translocation activity of the intrinsic membrane sector. (1980) (67)
Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. (1999) (67)
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. (2000) (66)
Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality. (2015) (66)
Role of naturally arising regulatory T cells in hematopoietic cell transplantation. (2006) (65)
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. (2000) (65)
A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. (2013) (64)
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. (2005) (60)
Granulocyte colony-stimulating factor-induced comobilization of CD4- CD8- T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors. (1997) (59)
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. (2005) (59)
T cells expressing chimeric antigen receptor promote immune tolerance. (2017) (58)
Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis (2017) (57)
Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. (1995) (56)
Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. (2017) (56)
Nasal continuous positive airway pressure in atelectasis. (1987) (56)
Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. (1996) (54)
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. (2012) (54)
MLL leukemia induction by genome editing of human CD34+ hematopoietic cells. (2015) (54)
CD2-mediated IL-12–dependent signals render human γδ-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies (2000) (54)
Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization (2016) (52)
Identification of Orai1 channel inhibitors by using minimal functional domains to screen small molecule microarrays. (2014) (52)
CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. (2011) (52)
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. (2000) (51)
Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. (2013) (51)
Cellular immunotherapy and autologous transplantation for hematologic malignancy (1997) (51)
CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells (2001) (51)
CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. (2010) (50)
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. (2021) (50)
Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation1 (2009) (50)
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. (1991) (49)
CD31 mismatching affects marrow transplantation outcome. (2001) (49)
Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. (2002) (49)
Unipotent Megakaryopoietic Pathway Bridging Hematopoietic Stem Cells and Mature Megakaryocytes (2015) (48)
Biology and clinical effects of natural killer cells in allogeneic transplantation (2010) (48)
A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. (1994) (48)
Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. (2019) (48)
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. (1997) (47)
Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. (2017) (47)
Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. (1994) (46)
Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes. (1990) (46)
Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations. (1994) (46)
Effects of CSFs in preleukemia. (1990) (45)
Thomas' hematopoietic cell transplantation : stem cell transplantation (2015) (45)
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. (2000) (45)
Regulation of different inflammatory diseases by impacting the mevalonate pathway (2009) (45)
CD101 Surface Expression Discriminates Potency Among Murine FoxP3+ Regulatory T Cells1 (2007) (44)
Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. (2015) (44)
Role of NKG 2 D signaling in the cytotoxicity of activated and expanded CD 8 T cells (2004) (43)
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. (2007) (42)
Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease (2015) (42)
Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy (2015) (42)
CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. (2000) (41)
CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. (2020) (40)
Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. (1990) (39)
Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation (2017) (39)
Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation. (2005) (39)
CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. (2005) (37)
Analysis of human hematopoietic stem cell populations. (1994) (36)
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. (2001) (36)
ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation. (2011) (35)
Mapping immune processes in intact tissues at cellular resolution. (2012) (35)
Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. (2012) (34)
DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease. (2016) (34)
Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells (2005) (34)
Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET (2020) (33)
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. (2019) (32)
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. (2020) (32)
The use of the polymerase chain reaction for the detection of minimal residual malignant disease. (1991) (31)
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. (2009) (31)
Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. (2010) (29)
Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models. (2014) (29)
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. (2012) (28)
CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells. (2007) (28)
Generation of T cells from cytokine-mobilized peripheral blood and adult bone marrow CD34+ cells. (1994) (28)
Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. (2018) (26)
Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase (1994) (26)
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. (1999) (26)
Freeze and Thaw of CD4+CD25+Foxp3+ Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease (2015) (25)
Hodgkin disease‐derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis (2001) (24)
Ferrichrome transport in inner membrane vesicles of Escherichia coli K12. (1978) (24)
Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion (2020) (24)
Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance. (2021) (24)
Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. (1990) (23)
Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. (1994) (23)
G-CSF and peripheral blood progenitor cells (1992) (23)
Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells. (2013) (22)
Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. (2014) (22)
Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution (2018) (22)
Sirolimus and Mycophenolate Mofetil as Graft-versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation (2008) (22)
H+-ATPase of Escherichia coli uncB402 mutation leads to loss of chi subunit of subunit of F0 sector. (1983) (21)
The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. (1993) (21)
Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. (2014) (20)
Enrichment of bone marrow and blood progenitor (CD34+) cells by density gradients with sufficient yields for transplantation. (1995) (20)
NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment (2016) (19)
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease (2015) (19)
Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion (2014) (19)
A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model (2013) (18)
Lymphokine-activated killer cell activity after cryopreservation. (1989) (17)
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. (2010) (17)
Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission (1993) (17)
TNF-Alpha Priming Enhances CD4+FoxP3+ Regulatory T Cell Suppressive Function in GVHD Prevention and Treatment (2016) (17)
High dose etoposide‐based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma (1996) (17)
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy (2021) (16)
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies (1995) (16)
Autografting in chronic myelogenous leukemia: new questions. (1995) (16)
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. (2021) (16)
A killer choice for cancer immunotherapy (2014) (16)
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. (2000) (16)
Cancer vaccines and T cell therapy. (2013) (16)
Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. (2020) (16)
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. (1994) (15)
Plasmacytoid Dendritic Cells Take Up Opsonized Antigen Leading to CD4+ and CD8+ T Cell Activation In Vivo1 (2008) (15)
A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma (1995) (15)
Methods for imaging cell fates in hematopoiesis. (2007) (15)
Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation. (2006) (14)
Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease. (2007) (14)
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial (2020) (13)
In vitro and in vivo activity of murine lymphokine‐activated killer cells after cryopreservation (1992) (13)
Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity (2012) (13)
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. (2006) (13)
The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes. (1990) (13)
Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease (2019) (13)
Use and Toxicity of the Colony-Stimulating Factors (1993) (13)
Regulatory T Cell Immunotherapy in Immune-Mediated Diseases (2015) (12)
Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease (2020) (12)
Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. (2019) (12)
128Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation (2003) (12)
Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation. (2011) (11)
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma (2012) (11)
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. (2000) (11)
Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming (2021) (11)
The role of N-linked carbohydrate residues in lymphokine-activated killer cell-mediated cytolysis. (1994) (11)
A novel technique for the enrichment of primary ovarian cancer cells. (2007) (10)
Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets. (2017) (10)
Autologous hematopoietic cell transplantation for high-risk ALL (2011) (10)
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. (2017) (10)
Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib (2016) (10)
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-hodgkins lymphoma (FL) beyond first complete response or first partial response (2008) (9)
Role of regulatory T cell populations in controlling graft vs host disease. (2011) (9)
Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd (2008) (9)
Is Nitrous Oxide Safe for Bone Marrow Harvest? (1995) (9)
Engraftment of chronic myeloid leukemia in SCID mice (1998) (9)
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY (2011) (9)
Rapid engraftment after allogeneic transplantation of density‐enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies (2001) (9)
Rapamycin and IL-2 Prevents Lethal Acute Graft-Versus Host Disease by Expansion of Donor Type CD4+CD25+Foxp3+ Regulatory T Cells. (2009) (9)
Type II HMG-CoA Reductase Inhibitors (Statins) Provide Acute-Graft-Versus-Host Disease Protection by Th-2 Cytokine Induction While Sparing Graft-Versus-Leukemia Activity. (2006) (9)
Cytokine Induced Killer (CIK) Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation. (2006) (9)
Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. (2019) (8)
Introduction to the review series on "Advances in hematopoietic cell transplantation". (2014) (8)
Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using total lymphoid irradiation and anti-thymocyte globulin conditioning (2015) (8)
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report (2019) (8)
A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease (2016) (8)
High-Parametric Evaluation of Human Invariant Natural Killer T Cells to Delineate Heterogeneity in Allo- and Autoimmunity. (2020) (8)
Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence. (2002) (8)
HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. (2017) (8)
Comprar Thomas' Hematopoietic Cell Transplantation, 4th Edition | Karl G. Blume | 9781405153485 | Wiley (2009) (8)
What We Have Learned and What We Need to Know (2006) (7)
Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma (2018) (7)
Effects of granulocyte colony-stimulating factor therapy on in vitro hemopoiesis in myelodysplastic syndromes. (1995) (7)
Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report (2022) (7)
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (7)
Early CD 30 signaling is critical for adoptively transferred CD 4 CD 25 regulatory T cells in prevention of acute graft-versus-host disease (2007) (7)
Immune regulation in hematopoietic cell transplantation (2019) (7)
Engraftment of embryonic stem cells and differentiated progeny by host conditioning with total lymphoid irradiation and regulatory T cells. (2015) (7)
Promise and Challenges of Human Regulatory T Cells in the Clinic (2007) (6)
Long Term Results of Autologous Hematopoietic Cell Transplantation (AHCT) for Peripheral T Cell Lymphoma: The Stanford Experience. (2007) (6)
A novel antibody-cell conjugation method to enhance and characterize cytokine-induced killer cells. (2020) (6)
Ex Vivo Generated Donor Central Memory CD8 T Cells, Previously Shown to Enhance Engraftment of Allogeneic Bone Marrow, Also Exhibit Significant GVL Activity without Causing Gvhd In An In Vivo b Cell Lymphoma Model (2010) (6)
Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging. (1992) (6)
European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation (2014) (6)
Bone marrow transplantation for hematologic malignancies: the Stanford experience. (1990) (6)
Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. (2020) (6)
IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation. (2013) (6)
Assays to determine hematopoietic stem cell content in blood or marrow grafts. (1999) (6)
Treatment with agonistic DR 3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease (2015) (5)
Inhibition of Protein Geranylgeranylation and Farnesylation Protects Against GVHD (2011) (5)
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. (1999) (5)
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma (2020) (5)
Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. (2011) (5)
Invariant natural killer T-cell subsets have diverse graft-versus-host-disease – preventing and antitumor effects (2021) (5)
Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility (2013) (5)
Prevention of acute graft-versus-host disease despite compensatory function of lymphoid organs in vivo (2006) (5)
Prediction of response to G-CSF and epo treatment for the anaemia of myelodysplastic syndromes (MDS) (1994) (5)
Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation. (1997) (5)
Missplicing of Glycogen Synthase Kinase 3β: A Potential Mechanism of Blast Crisis Chronic Myeloid Leukemia Stem Cell Generation. (2007) (4)
Immunoglobulin G Fc Polymorphism Is Correlated with Rituximab-Induced Neutropenia Following Autologous Hematopoietic Cell Transplantation. (2004) (4)
Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects. (2021) (4)
Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients (2015) (4)
Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant. (2020) (4)
calcineurin-dependent interleukin-2 production Inhibition of CD4+CD25+ regulatory T-cell function by (2013) (4)
Prevention of Acute Graft-Versus-Host Disease Despite Compensatory Function of Lymphoid Organs In Vivo. (2005) (4)
Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma. (2016) (4)
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma (2021) (4)
Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma (2012) (4)
Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD. (2021) (4)
Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients. (2021) (3)
NKT Cells Are Potent Regulators of GVHD Following Adoptive Transfer in Allogeneic BMT. (2007) (3)
Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin Confirm a Low Incidence of Graft Versus Host Disease (GVHD) and Retained Graft Anti-Tumor Activity. (2006) (3)
Safety Of Nitrous Oxide For Bone Marrow Harvests (1992) (3)
Autologous Cytokine-Induced Killer Cells as Post-Transplant Cellular Immunotherapy. (2007) (3)
Rituximab Infusion Two Months after Nonmyeloablative Transplantation Maintains B-Cell Disease Control with Minimal GVHD. (2006) (3)
Enrichment of allogeneic CD34+ cells and T cell depletion by percoll density gradient centrifugation. (1996) (3)
Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes (2011) (3)
Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants (2020) (3)
Differential impact of mTOR inhibition on CD4CD25Foxp3 regulatory T cells as compared to conventional CD4 T cells Running title: Impact of mTOR inhibition on Treg and Tconv (2007) (3)
Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies (2022) (3)
Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning (2016) (3)
283: Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD (2007) (3)
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells. (2013) (3)
CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy (2021) (3)
In Vivo Imaging of GVHD and GVL (2019) (3)
A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma (2005) (3)
CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (2020) (3)
Haploidentical Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Conditioning Protects Against Acute Graft Versus Host Disease (GVHD). (2005) (3)
Management of Relapse after Hematopoietic Cell Transplantation (2009) (3)
NK Cells Suppress Gvhd by Directly Inhibiting Activated Alloreactive T Cells through An NKG2D-Mediated Mechanism (2008) (2)
Cells and Hematopoietic Progenitor Cells ( CD 34 " ) in the Blood of Normal Donors (1997) (2)
Bioluminescent Imaging of Human Leukemic Stem Cell Engraftment. (2005) (2)
IL-2 Plus IL-15 Leads to Enhanced Ex Vivo Expansion of Human Invariant Natural Killer T Cells (2017) (2)
Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms (2015) (2)
Prevention of Acute Graft-Versus-Host Disease by CD4+CD25+ Regulatory T Cells Is Dependent on the CD30/CD153 Pathway. (2005) (2)
Granulocyte colony stimulating factor plus erythropoietin for the maintenance treatment of the anemia of myelodysplastic syndromes (1994) (2)
Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity (2022) (2)
Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo. (2022) (2)
Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity (2020) (2)
CD4+CD25+ Regulatory T Cells Enhance Immune Reconstitution Following Allogeneic Hematopoietic Cell Transplantation by Protecting Thymic and Lymphoid Compartments from Graft-Versus-Host Disease Damage without Impacting T Cell Repertoire Development. (2006) (2)
Immune regulatory networks in the post-transplant setting. (2008) (2)
In vivo imaging of graft-versus-host disease and graft-versus-leukemia (2013) (2)
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. (2021) (2)
CD4+ Invariant Natural Killer T Cells Protect from Acute Graft-Versus-Host Disease Lethality through a Dramatic Expansion of Donor-Derived CD4+FoxP3+ Regulatory T Cells (2014) (2)
Functional Comparison of Freshly Isolated and Ex-Vivo Expanded CD4+CD25+Foxp3+ Regulatory T Cells in Suppressing Murine Acute GvHD (2008) (2)
Effects of treatment of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor. (1990) (2)
Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure (2010) (2)
Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy (2015) (2)
Allogeneic Bone Marrow Transplantation for BCR-ABL Positive Acute Lymphoblastic Leukemia (2001) (2)
Emerging Therapies for Chronic GVHD (2002) (2)
Engineered IL-2 Cytokine-Cytokine Receptor Complex Enables Selective Expansion of Regulatory T Cells and Facilitates Establishment of Organ Transplantation Tolerance (2020) (2)
Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis (2015) (2)
Analysis of T cell Repertoire and Transcriptome Identifies Mechanisms of Regulatory T cell (Treg) Suppression of GvHD. (2022) (2)
Minimal residual disease (1998) (2)
Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS) (2014) (2)
Therapy of hematopoietic disorders with recombinant colony-stimulating factors. (1992) (2)
Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (2021) (2)
Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study (2020) (2)
Mesenchymal Stem Cells (MSC) Are Not Intrinsically Immune Privileged: Direct Demonstration in TCR Transgenic Mice and by Imaging of Allogeneic Luciferase+ MSC in Immune Competent Vs Immune Deficient Mice (2008) (1)
Engraftment and Survival Following Non-Myeloablative Allogeneic Peripheral Blood Hematopoietic Cell Transplantation for Malignant Diseases Is Affected by CD8 + T-Cell Dose. (2004) (1)
Distinct Immune Regulatory Potential of Invariant Natural Killer T (iNKT) Cell Subsets: iNKT2 and iNKT17, but Not iNKT1, Protect from Graft-Versus-Host-Disease (2019) (1)
Impact of mTOR Inhibition on FoxP3+ Regulatory T Cells as Compared to Conventional T Cells after Allogeneic Bone Marrow Transplantation. (2006) (1)
Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome (2004) (1)
Donor Requirements For CD4+CD25+FoxP3+ Regulatory T Cells Capable Of Suppressing CD4+ and CD8+ Conventional T Cell Proliferation and Graft Versus Host Disease (2013) (1)
Immunotherapy of Primary Ovarian Cancer Using Autologous Cytokine Induced Killer Cells Retargeted with Bispecific Antibodies: A Preclinical Study. (2005) (1)
Loss of CD62L Expression in CD4+FoxP3+ Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models (2014) (1)
Consolidative CD8+ Memory T-Cell Donor Lymphocyte Infusion Augments Donor Chimerism with a Low Risk of Gvhd Following Matched Related Donor Hematopoietic Cell Transplantation (2017) (1)
TNF-Alpha Priming Enhances CD4(+) FoxP3(+) Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment (2015) (1)
PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA (2017) (1)
Ewing's sarcoma/PNET tumor cell lines express Her2/neu which can be utilized as a target by redirected T cells (2000) (1)
Welcome to Blood Advances. (2016) (1)
Allogeneic hematopoietic cell transplant for normal karyotype acute myeloid leukemia: Indirect evidence of selection for adverse molecular profile (2015) (1)
The use of colony stimulating factors in clinical bone marrow transplantation. (1992) (1)
Third Party Invariant Natural Killer T Cells Protect from Graft-Versus-Host Disease Lethality through Expansion of Donor CD4 + FoxP3 + Regulatory T Cells (2014) (1)
Non-Myeloablative Conditioning of Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Protects Against Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (HCT) but Retains Anti-Tumor Activity. (2004) (1)
Enhanced immune reconstitution and function by CD4+CD25+ regulatory T cells following allogeneic hematopoietic cell transplantation (2006) (1)
Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies (2008) (1)
S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES (2022) (1)
Imaging alloreactive T cells provides early warning of organ transplant rejection (2021) (1)
SECTION X: REGULATORY T CELLS Natural and Expanded CD4 1 CD25 1 Regulatory T Cells in Bone Marrow Transplantation (2011) (1)
Inflammatory TH1 Cytokines in Target Tissues Promote the Recruitment of Alloreactive T Cells in Graft-Versus-Host Disease. (2009) (1)
Only the CD62L (cid:1) subpopulation of CD4 (cid:1) CD25 (cid:1) regulatory T cells protects from lethal acute GVHD (2005) (1)
protects from lethal acute GVHD Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells (2013) (1)
In Vivo Effects of Cyclosporine A, Mycophenolate Mofetile and Rapamycin on Adoptively Transferred CD4+CD25+ Regulatory T Cells in Prevention of Experimental Acute Graft-Versus-Host Disease. (2005) (1)
Three-Dimensional Visualization of Immunological Processes of Entire Organs in Subcellular Resolution. (2009) (1)
Selective Expansion of Human Regulatory (CD4+CD25+CD127LowFOXP3+) Cells to High Purity by Inhibiting Expansion of CD4+CD25+CD127HighFOXP3-Conventional T Cells with Rapamycin. (2006) (1)
Natural Killer Cell Adoptive Immunotherapy Is Hampered by A Rapid Development of NK Cell Dysfunction Characterized by Loss of Effector Mechanisms and Downregulation of the Transcription Factors T-Bet and Eomesodermin; Definition and Possible Mechanism of NK Cell Exhaustion (2011) (1)
Depletion of Host Dendritic Cells During the Effector Phase of GVHD Enhances Acute GVHD and Mortality (2012) (1)
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents (2019) (1)
Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results (2011) (1)
Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients (2019) (1)
Total lymphoid irradiation and transplantation tolerance (2006) (1)
Immunotransplant Expands Vaccine-Induced Memory T Cell Responses In Patients With Mantle Cell Lymphoma (2013) (1)
Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation (2016) (1)
Silencing human NKG2D, DAP10 and DAP12 reduces cytotoxicity of in vivo activated CD8+ T and NK cells (2005) (1)
Early Treatment with CD4+CD25+ Regulatory T Cells Provides Prolonged Suppressive Effects Which Control Evolving but Not Established Graft-Versus-Host-Disease. (2005) (1)
In Vivo Trafficking of CD4+CD25+ Regulatory T-Cells in Allogeneic Recipients Using Bioluminescence Imaging. (2004) (1)
The Expansion of Gastrointestinal-associated αβ T Cell Clones in Peripheral Blood Over Time Is a Disease Feature of Severe Acute Graft-Versus-Host Disease (2012) (1)
following allogeneic hematopoietic cell transplantation Regulatory T cells and natural killer T cells for modulation of GVHD (2013) (1)
Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). (2020) (1)
CD 4 1 invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD 4 1 CD 25 1 FoxP 3 1 regulatory T cells (2014) (1)
TRANSPLANTATION Mast cells suppress murine GVHD in a mechanism independent of CD4 1 CD25 1 regulatory T cells (2013) (0)
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide Mobilization Vs. G-CSF ± Plerixafor Mobilization in the Lenalidomide Era (2021) (0)
Transcriptome Identifies Mechanisms of 1 Regulatory T cell ( Treg ) Suppression of Acute Graft-versus-Host-Disease 2 3 (2022) (0)
cells T + regulatory T cells compared with conventional CD4 + Foxp3 + CD25 + Differential impact of mammalian target of rapamycin inhibition on CD4 (2008) (0)
CD62L and CD31 Matching Are Independent Risk Factors for Survival after Bone Marrow Transplantation. (2005) (0)
Invariant Natural Killer T Cell Subsets Have Diverse Functions: iNKT2 and iNKT17 Protect from Graft-Versus-Host-Disease, Whereas iNKT1 Have Antitumor Potential (2018) (0)
Bone marrow-derived mesenchymal stem cells are recruited to the brain but do not differentiate into neuronalphenotypes in mouse models of stroke (2010) (0)
Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers (2015) (0)
Utilization of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation (0)
T Cell Trafficking in Acute GVHD: In Vivo Bioluminescence Evaluation To Elucidate the Role of Different Lymphatic Organs. (2004) (0)
Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma (2022) (0)
Isolation of Both Normal and Leukemic Cells Within the Hematopoietic Stem Cell Compartment of Chronic Myelogenous Leukemia Mobilized Peripheral Blood (2020) (0)
Comparison of four categorized risk scoring systems for analyzing outcome in advanced MDS (1994) (0)
Compositions and methods for the protection of organs, tissues and cells from damage mediated by the immune system (1999) (0)
Tissue Damage and Lymphoma Derived Chemoattractive Signals Impact Regulatory T Cell Trafficking After Allogeneic Hematopoietic Cell Transplantation. (2009) (0)
NK Cells Induce Alloreactive Donor T Cell Apoptosis and Decrease Proliferation in GVHD Induction. (2007) (0)
Development of a minimally invasive bone marrow harvest device and method for the rapid extraction of bone marrow for use in bone marrow transplantation and stem cell therapy (2005) (0)
Inhibitory Effects of Cytotoxicity of Cytokine Activated and Expanded Human CD8+ T Cells by a Human NKG2D Alternative Splice Variant. (2004) (0)
Murine CIK cells show tumor specific cytolysis in CD107a based degranulation analysis (2005) (0)
Use of R-spondin1, An Intestinotrophic Mitogen, in the Treatment of Murine Graft-Versus-Host Disease (2008) (0)
Anti-CD22 CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (2021) (0)
Equivalence of 2 Effective Graft-Versus-Host Disease Prophylaxis Regimens : Results of a Pro s p e c t i ve (2000) (0)
The Use of Monoclonal Antibody Directed Chimeric Antigen Receptors to Guide T Cell and Treg Homing for GvHD Control and Tissue Tolerance in Murine Models (2016) (0)
In vivo trafficking and proliferation of natural killer cells in murine models of bone marrow transplantation (2006) (0)
Infusion of Syngeneic Apoptotic Cells Prior to Bone Marrow Transplantation Decreases Tcell Proliferation and Increases Survival (2012) (0)
Assessment of Tumor Depletion Following Tandem Mobilization in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (2014) (0)
Host CD4+CD25+FoxP3+ Regulatory T Cells Facilitate Donor Engraftment Without Impacting Graft Versus Host Disease Onset After Major-Mismatched Hematopoietic Stem Cell Transplantation (2013) (0)
using in vivo bioluminescence imaging Revealing lymphoma growth and the efficacy of immune cell therapies (2013) (0)
39: Differential impact of mTOR inhibition on FoxP3+ regulatory T cells as compared to conventional T cells after allogeneic bone marrow transplantation (2007) (0)
Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies. (2009) (0)
CT-524 Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies. (2022) (0)
A Novel Antibody-Cell Conjugation Method to Enhance Cellular Therapies for the Treatment of Hematological Malignancies (2017) (0)
Allogeneic Environment and Tissue Damage Provide Critical Stimuli for Regulatory T Cell Expansion and Survival In Vivo after Hematopoietic Cell Transplantation. (2006) (0)
Housing Deadline for Tandem BMT Meetings (2002) (0)
NK cell reconstitution is improved during allogeneic hematopoietic stem cell transplantation by infusion of NK cell-committed progenitor cells (HEM5P.233) (2015) (0)
A killer choice for cancer immunotherapy (2014) (0)
Orca-T, a High-Precision Cell Therapy, for the Treatment of Hematologic Malignancies in Patients with 7/8 Mismatch Donors (2023) (0)
The Expansion of Gastrointestinal-Associated αβ T Cell Clones in Peripheral Blood Associates with Severe Steroid Refractory GVHD (2013) (0)
Analytical Validity of Deep Sequencing to Characterize Tissue-Infiltrating Lymphocytes (2012) (0)
Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant (2020) (0)
F.122. Deletion in H-NKG2D Ligand Effects Tumors Resistance to T-Cells Mediated Cytotoxicity (2006) (0)
Erratum (2005) (0)
the Stanford University Results and Prognostic Indices of Transplantation for Recurrent or Refractory Hodgkin's Disease: Analysis High-Dose Therapy and Autologous Hematopoietic Progenitor Cell (2013) (0)
The Use of Granulocyte Colony Stimulating Factor for the Treatment of Patients with Myelodysplastic Syndromes (1992) (0)
allogeneic transplantation effective strategies to control graft-versus-host disease following In vivo dynamics of regulatory T-cell trafficking and survival predict (2013) (0)
third-party central memory CD8 T cells - nonreactive anti A new approach for eradication of residual lymphoma cells by host (2013) (0)
Recruitment and Differentiation of Endogenous Bone Marrow.Derived Mesenchymal Stem Cells after cerebral Ischemia (2012) (0)
MAb therapy comes of age (2000) (0)
Stem Cell Transplantation Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic (2013) (0)
Recipient-speci ﬁ c T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant (2020) (0)
Karl Georg Blume, MD (2013) (0)
Multi-parameter optical imaging of immune cell activity in chimeric antigen receptor T-cell and checkpoint blockade therapies (2021) (0)
Foxp3+ regulatory T Cells Maintain Bone Marrow Microenvironment for B Cell Differentiation from Hematopoietic Stem Cells (2016) (0)
Differential effects of immunosuppressants on adoptively transferred CD4+CD25High regulatory T cells in prevention of experimental acute graft-versus-host disease (2006) (0)
Trafficking and Expansion of NK Cells in Murine Models of Bone Marrow Transplantation. (2005) (0)
Impact of Conditioning Regimen and Donor Type on Outcomes of Allogeneic Stem Cell Transplant for Myelofibrosis – a Single Institutional Experience (2021) (0)
Adoptive Transfer Of Ex Vivo “Educated” CD4+CD25+FoxP3+ Regulatory T Cells Effectively Treats Acute Graft Versus Host Disease Preserving Graft Versus Tumor Effect (2013) (0)
New Strategies for Fungal Infections after Hematopoietic Cell Transplantation : Prevention or Preemption ? (2007) (0)
Bioluminescent tracking of candidate leukemic stem cell engraftment in immunocompromised mice (2005) (0)
(CSF) and granulocyte-monocyte CSF between recombinant human granulocyte colony-stimulating factor hematopoiesis in the myelodysplastic syndromes: comparison Impact of marrow cytogenetics and morphology on in vitro (2011) (0)
A Signal Hierarchy Model of Alloreactive T Cell Trafficking for the Organ Manifestation in Acute Graft-Versus-Host Disease. (2006) (0)
Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation (2013) (0)
Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation (2020) (0)
Revealing kinetics of cytokine induced killer cell trafficking and survival in vivo (2006) (0)
Erratum: Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation (Transplantation (July 15, 2005) 80, (134-139)) (2005) (0)
T-cell dose peripheral blood hematopoietic cell transplantation is affected by CD8+ Engraftment and survival following reduced-intensity allogeneic (2013) (0)
CD8+ T cells Role of NKG2D signaling in the cytotoxicity of activated and expanded (2010) (0)
ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD (2022) (0)
Adoptive Transfer of NKT Cells Reduces GVHD Severity Via an IFN-γ And IL-4 Dependent Mechanism (2009) (0)
Single-cell Transcriptomics Reveal Different Maturation Stages and Sublineages Commitment of Human Thymic Invariant Natural Killer T cells (2022) (0)
Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4 (cid:1) CD25 (cid:1) Foxp3 (cid:1) regulatory T cells (2011) (0)
Interference with Inflammation Induced Endothelial Receptors Prevents Acute Graft-Versus-Host Disease. (2009) (0)
Predictive Markers for Acute Graft-Versus-Host Disease in the Peripheral Blood - Surface Receptor Profile Defines Alloreactive T Cells In Vivo . (2006) (0)
Cytokines for the Treatment of Myelodysplastic Syndromes and Other Bone Marrow Failure States (1999) (0)
Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit without Gvhd (2016) (0)
Membranous Glomerulonephritis and Nephrotic Syndrome as a Late Manifestation of Chronic Graft-Versus-Host Reaction Following Allogeneic Transplantation for Hematologic Malignancy. (2006) (0)
Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience (2014) (0)
Definition of a Diagnostic Window Prior to the Onset of Clinically Apparent Acute Graft-Versus-Host Disease. (2010) (0)
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. (2023) (0)
152: Long Term Remission in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients After Allogeneic Myeloablative Hematopoietic Cell Transplantation (HCT) Using Matched Related Donors: The 20 Year Experience at Stanford University and City of Hope National Medical Center (2008) (0)
Mast Cells Suppress GVHD in a Mechanism Independent of CD4+CD25+ Regulatory T Cells (2011) (0)
Allogeneic Hematopoietic Cell Nanoparticle-Labeled Dendritic Cells Tolerogenic Function of Inhibition on Lymphoid Homing and Impact of Mammalian Target of Rapamycin (2008) (0)
Assessment of the near-Infrared Fluorescent Protein FP635 for Dynamic In Vivo Imaging in Models of Adaptive Immune Responses. (2009) (0)
Prevention and Therapy of Relapse Following Autologous Hematopoietic Cell Transplantation (2007) (0)
Assessment Of The Utility Of Subset Donor Chimerism For Predicting Event-Free Survival After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using TLI And ATG (2010) (0)
TRANSPLANTATION CD 4 1 invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD 4 1 CD 25 1 FoxP 3 1 regulatory T cells (2014) (0)
The Use of Monoclonal Antibody Directed Chimeric Antigen Receptors to Facilitate Conventional T Cell and Treg Control of GvHD and Tissue Tolerance in Murine Models (2016) (0)
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era (2020) (0)
47: CD4+CD25+ regulatory T cells enhance immune reconstitution following allogeneic hematopoietic cell transplantation by protecting thymic and lymphoid compartments from graft-versus-host disease damage without impacting T cell repertoire development (2007) (0)
Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects (2022) (0)
8Trafficking of ex vivo expanded donor derived dendritic cells after allogeneic BMT (2003) (0)
Role of NKG2D in the induction of mouse natural killer cell exhaustion (IRC8P.473) (2014) (0)
The role of peyer’s patches and mesenteric lymph nodes in acute GVHD: a study guided by bioluminescence imaging in vivo (2004) (0)
TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN (2013) (0)
Analysis of Expanded Human Cytokine Induced Killer Cells for Cellular Therapy. (2005) (0)
A Proinflammatory Invariant Natural Killer T Cells Phenotypic State Associates with Human Graft-Versus-Host Disease Onset and Response (2018) (0)
A Proinflammatory Invariant Natural Killer T Cell Phenotypic State Associates with Human Graft-Versus-Host Disease Onset (2019) (0)
Agonistic Anti-DR3 Antibody Expands Treg and Reduces Experimental Acute Graft-Versus-Host Disease (2013) (0)
cell transplantation for aggressive non-Hodgkin's lymphoma Rituximab as adjuvant to high-dose therapy and autologous hematopoietic (2013) (0)
Anen, tissue and cells against damage caused by the immune system (1999) (0)
Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation (2015) (0)
Early treatment with CD4+CD25+ regulatory T cells provides prolonged suppressive effects which control evolving but not established graft-versus-host-disease (2006) (0)
(F2) Granulocyte colony-stimulating factor (G-CSF) in the treatment of myelodysplastic syndromes (MDS) (1991) (0)
Cellular immunotherapy redirected by bispecific antibodies in primary ovarian cancer cells: A preclinical study. (2006) (0)
In vivo kinetics of acute graft-versus-host disease in conditioned vs. unconditioned hosts (2006) (0)
Activation of DR3 Signaling Expands Recipient Derived Regulatory T Cells and Enhances Donor Immune Reconstitution Derived from Allogeneic Hematopoietic Stem Cells (2014) (0)
Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis (2020) (0)
erythropoietin: evidence for in vivo synergy with recombinant human granulocyte colony-stimulating factor and Maintenance treatment of the anemia of myelodysplastic syndromes (2011) (0)
Isolation and Characterization of Human CD4+CD25+ T Regulatory Cells for Early Phase Clinical Trials in Hematopoietic Cell Transplantation. (2005) (0)
Adoptively Transferred NK Cells Home to Tumor Sites and Accumulate With Tumor Growth But Do Not Lead to Tumor Regression in a Murine B-Cell Lymphoma Model (2011) (0)
Tissue-Specific Homing of Natural Killer Cells in Allogeneic Bone Marrow Transplantation. (2006) (0)
Differential Impact of Host Derived Interleukin-18 on Regulatory and Conventional T Cell Expansion Following Murine Allogeneic Hematopoietic Cell Transplantation. (2007) (0)
Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma (2020) (0)
Early Results of a Phase I Study of CAR-T Cells + NKTR-255 (PEG-IL-15) in Adults with R/R ALL (2023) (0)
CD4+ Invariant Natural Killer T Cells Require NKG2D To Protect From Lethal Acute Graft-Versus-Host Disease (2013) (0)
Chronic stimulation results in NK cell function impairment mediated by NKG2D (2017) (0)
Silica-Induced Impairment of Macrophage Function Reduces GVHD Severity and Improves Survival (2011) (0)
Third Party Invariant Natural Killer T Cells Protect from Lethal Graft-Versus-Host Disease through Donor CD4+CD25+FoxP3+ Regulatory T Cells (2015) (0)
Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study (2021) (0)
Human CIK Maintain Their In Vitro and In Vivo Anti-Tumor Ability after Cryopreservation. (2005) (0)
Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity (2008) (0)
Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms. (2012) (0)
Allogeneic Cytokine-Induced Killer Cells Traffick to GVHD Target Tissue but Cause Less GVHD, While Retaining Tumor Cytotoxicity and Facilitating Bone Marrow Engraftment. (2006) (0)
Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors (2021) (0)
Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation. (2016) (0)
Cell Stem Cell Tolerance to ESCs and iPSCs by Costimulatory Blockade well as the trafficking and costimulation of T cells (2011) (0)
Treatment of Donors with Death Receptor 3 Agonistic Fusion Protein TL1A-Ig (with and Without Low Dose IL-2) Leads to Regulatory T Cell Expansion and Activation with Reduction in Graft-Versus-Host Disease (2018) (0)
Regulatory T Cell Therapy for Immunomodulation After Allogeneic Hematopoietic Cell Transplantation (2010) (0)
301: Selective expansion of human regulatory (CD4+CD25+CD127LowFOXP3+) cells to high purity by inhibiting expansion of CD4+CD25+CD127HighFOXP3- conventional T cells with rapamycin (2007) (0)
Engineering Human Invariant Natural Killer T (iNKT) Cells to Overexpress Immunomodulatory Cytokines (2021) (0)
Control of alloreactivity using transient expression of a monoclonal antibody directed chimeric antigen receptor in conventional and regulatory T cells (2017) (0)
Similarities In the Initial Events of Murine Gvhd Across Minor. as Compared to Major, Histocompatibility Barriers. (2010) (0)
chronic myeloid leukemia The effects of imatinib mesylate treatment before allogeneic transplant for (2012) (0)
Development of a Minimal Residual Disease Model for Ovarian Cancer Using Bioluminescence in an Immunocompetent Mouse Model (2007) (0)
Mast Cells Reduce Gvhd Severity In Allogeneic Transplantation by Reducing the Proliferation of Conventional T Cells (2010) (0)
756. The Use of Immune Cell Trafficking to Deliver an Oncolytic Virus to Tumors (2005) (0)
21: Preparation of Highly Purified Regulatory T Cells for Clinical Applications (2008) (0)
In vivo spatial and temporal analyses in mice reveal redundancy of lymphoid tissues in inducing acute GVHD after allogeneic hematopoietic cell transplantation (2005) (0)
In vivo trafficking of CD4+CD25+ regulatory T-cells in allogeneic recipients using bioluminescence imaging (2005) (0)
Isolation and characterization of human CD4+CD25+ T regulatory cells for early phase clinical trials in hematopoietic cell transplantation (2006) (0)
100 Already? (2021) (0)
Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma. (2008) (0)
New Pre-Transplant Regimens (2020) (0)
Development of a minimal residual disease ovarian cancer model in immunocompetent mice (2008) (0)
Allogeneic Effector Cell Populations (2003) (0)
Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era (2022) (0)
A Novel Model of Pre-Emptive ECP Treatment Shows Significant Reduction of Gvhd-Related Mortality In Mice, (2011) (0)
Tracking T Cell Activation By OX40 Immuno-PET: A Novel Strategy for Imaging of Graft Versus Host Disease (2018) (0)
High Dose Therapy and Autologous Hematopoietic Cell Transplantation for Primary Refractory Diffuse Large Cell Non-Hodgkin’s Lymphoma. (2006) (0)
Functional analysis of tumor cell growth and clearance in living animals (1999) (0)
Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors (2016) (0)
Orca-T, a Precision Treg-Engineered Donor Product, in Myeloablative HLA-Matched Transplantation Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience (2021) (0)
Enhanced Immune Reconstitution and Function by CD4+CD25+ Regulatory T Cells Following Allogeneic Hematopoietic Cell Transplantation. (2005) (0)
TRANSPLANTATION Third-party CD 4 1 invariant natural killer T cells protect from murine GVHD lethality (2015) (0)
Memory Phenotype CD8+T Cells Are Superior to Naive CD8+T Cells in Separating Graft Anti-Tumor Activity From Gvhd After Bone Marrow Transplantation; Application to DLI. (2009) (0)
in minimal GVHD with retention of antitumor activity In vivo trafficking and survival of cytokine-induced killer cells resulting (2013) (0)
Immunobiology of Transplantation (2008) (0)
The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes (2022) (0)
Karl G. Blume, MD (1937-2013) (2013) (0)
Concordance of Next Generation Sequencing-Based Measurable Residual Disease between Peripheral Blood and Bone Marrow in Adults with Acute Lymphoblastic Leukemia Receiving Cellular Therapies (2021) (0)
The Double Benefit of ex-vivo Generated Anti 3rd Party CD8 T Cells With Central Memory Phenotype: Enhanced BM Engraftment Coupled With Marked GVL in the Absence of GVHD (2011) (0)
CD4+FoxP3+ Regulatory T Cells Promote B Cell Differentiation and Induce Tolerance to Bone Marrow Grafts (2015) (0)
iNKT Cell Stimulation with Liposomal Alpha/Gal/Cer Amplifies Proliferation of Adoptively Transferred Regulatory T Cells In Vivo and Reduces GvHD (2018) (0)
In Vivo Monitoring of Immunotherapies for Cancer in Intact Mice• 802 (1998) (0)
Gvhd Severity Is Regulated by the Adoptive Transfer Low Numbers of NKT Cells by a Mechanism Distinct From CD4+CD25+ Regulatory T Cells. (2009) (0)
Immune Phenotypic Quantification of Axicabtagene Ciloleucel and Brexucabtagene Autoleucel Demonstrates Lymphoma Histology Specific Differences in CAR19 Expansion and Toxicity (2023) (0)
A Functional Assay for Peripheral Blood T Cells to Predict Acute Graft-Versus-Host Disease. (2009) (0)
CD4+FoxP3+ Regulatory T Cells Regulate B Cell Differentiation and Induce Tolerance to Bone Marrow Grafts (2014) (0)
Impact of Donor T Cells on NK Cell Development after Allogeneic Hematopoietic Cell Transplantation (2016) (0)
Ex-Vivo Expanded And Freshly Isolated CD4+CD25+FOXP3+ Regulatory T Cells Suppress Murine Acute GVHD With Different Potency (2010) (0)
combination with erythropoietin (see comments) recombinant human granulocyte colony-stimulating factor in Treatment of the anemia of myelodysplastic syndromes using (2011) (0)
Left running head: HORWITZ et al. Right running head: RITUXIMAB AND AUTOTRANSPLANTATION FOR NHL Journal section: CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Rituximab as adjuvant to high dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin’s lymp (2003) (0)
LYMPHOID NEOPLASIA MLL leukemia induction by genome editing of human CD34 1 hematopoietic cells (2015) (0)
A preclinical study of cellular immunotherapy redirected by bispecific antibodies in uterine cell lines and primary cancer cells. (2006) (0)
The Graying of Clinical Transplantation (2006) (0)
Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. (2020) (0)
From blood to brain: Contribution of endogenous bone marrow-deriverd mesenchymal stem cells to the brain repair after stroke (2013) (0)
Repertoire of Murine T Cells in Target Tissues of MHC-Matched and -Mismatched Graft-Versus-Host Disease (2017) (0)
Orca-T Demonstrates Encouraging Overall Survival, Gvhd Reduction, and Tolerability in Patients with Hematologic Malignancies (2022) (0)
hematopoietic cell transplantation Reconstitution of NK cell receptor repertoire followingHLA-matched (2013) (0)
IL‐2 receptor engineering enhances regulatory T cell function suppressed by calcineurin inhibitor (2022) (0)
Autoimmune Diseases : When Homeland Security Fails (2004) (0)
Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin (2016) (0)
Regulatory T Cell Immunotherapy in Immune-Mediated Diseases (2015) (0)
Silensilencing Human NKG2D, DAP10 and DAP12 Reduces Cytotoxicity of in Vivo Activated CD8 + T and NK Cells. (2004) (0)
Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. (2021) (0)
Editorial from the new Editors (1997) (0)
Long-Term Follow-Up of Metastatic Breast Cancer Patients Receiving Highly Purified Autologous CD34+Thy-1+ Hematopoietic Stem Cells After High-Dose Chemotherapy (2011) (0)
Prevention of Acute Graft-Versus-Host Disease Using an Engineered Mouse Orthogonal IL-2/IL-2Rβ Regulatory T Cells (2021) (0)
RNA and TCR Sequencing Shed Light on Mechanisms of Treg Suppression in a Murine Model of Acute GvHD (2020) (0)
Cytotoxicity of human CD8+ T-cells and NK-cells is suppressed by an alternative NKG2D splice variant (90.19) (2009) (0)
Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort (2018) (0)
Tandem BMT meetings workshop descriptions (2004) (0)
Primary Human Acute Myeloid Leukemia Stem Cells Show Reduced Sensitivity To Natural Killer Cell-Mediated Killing (2010) (0)
The Inhibitory Receptor LAG-3 Is Not Essential for Regulatory T Cells Function but Influences Donor T Cell Potency in Acute Graft-Versus-Host-Disease (2011) (0)
Allogeneic Effector Cell Populations Separating GVL from GVHD (2013) (0)
Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells (2018) (0)
Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease (2022) (0)
335: Inhibition of HMG-CoA reductase activity with statins provides acute-graft-versus-host disease protection by Th-2 cytokine induction while sparing graft-versus-leukemia activity (2007) (0)
EX VIVO activated and expanded CD8+ T cells recognize malignant cells through a TCR independent and NKG2D dependent pathway (2004) (0)
Tracking T Cell Activation By OX40 ImmunoPET: A Novel Strategy for Imaging of Graft Versus Host Disease (2019) (0)
Activation of Regulatory T Cells with IL-2 and TNF-α to Promote Homing to the Gut and to Improve Acute GvHD Prevention (2019) (0)
CD22 CAR T Cell Therapy Induces Durable Remissions in Patients with Large B Cell Lymphoma Who Relapse after CD19 CAR T Cell Therapy (2023) (0)
Engraftment of Embryonic Stem Cells and Differentiated Progeny Following Host Conditioning with Total Lymphoid Irradiation and Regulatory T Cells (2015) (0)
Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Intensity (2014) (0)
New Guidelines Help Health Professionals Recognize and Manage Late Complications (2006) (0)
T Cell Activation In Vivo + CD8 and + Opsonized Antigen Leading to CD4 Plasmacytoid Dendritic Cells Take Up (2008) (0)
Extracellular release of damaged mitochondria induced by cytotoxic conditioning exacerbates GVHD (2023) (0)
Preface to the Fifth Edition (2005) (0)
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease Following Bone Marrow Transplantation, (2011) (0)
Single Dose Administration of ECP Treated Cells Prior to Transplantation Significantly Increases Survival in a MHC-Mismatched Model of Acute GvHD (2011) (0)
Kinetics of Murine GVHD Induction Across Minor and Major Histocompatibility Barriers (2011) (0)
Survival and homing of ex vivo expanded donor derived dendritic cells after allogeneic BMT (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roberts S. Negrin?

Roberts S. Negrin is affiliated with the following schools:

Roberts S. Negrin's Academic­Influence.com Rankings

Roberts S. Negrin's Degrees

Why Is Roberts S. Negrin Influential?

Roberts S. Negrin's Published Works

Published Works

What Schools Are Affiliated With Roberts S. Negrin?

Roberts S. Negrin's AcademicInfluence.com Rankings